|Metformin HCL||500 mg|
|Pioglitazone HCL||15 mg|
Click on the API name to know their properties
|Composit uses/ indication of TRIFORMIN :|
Non-insulin dependent diabetes mellitus, Softening and dilatation of cervix before mechanical cervical dilatation.
Diabetes mellitus, Hyperlipoproteinaemia, Insulin dependent diabetes mellitus, Insulin resistance, Non-insulin dependent diabetes mellitus, Obesity.
Diabetes mellitus type 2 in monotherapy and in combination with a sulfonylurea, metformin, or insulin.
|Composit contra indication of TRIFORMIN :|
Renal failure, Liver diseases, Diabetic coma, Impaired renal function, Insulin dependent diabetes mellitus.
|Composit side effects of TRIFORMIN :|
Thrombocytopenia, Cholestatic jaundice, Aplastic anemia, Hemolytic anemia, Leucopenia, Agranulocytosis, Pancytopenia, Hypersensitivity reactions, Renal failure, Hypoglycemia, Pneumonia. Coma, Cerebral damage. GI upset, Allergic skin reactions.
Diarrhea, vomiting and infection, Accidental injury, headache and infection, Indigestion and nausea, Nose inflammation.
Pharyngitis, oedema, headache, upper respiratory tract infection, sinusitis, anaemia, GI disturbances, weight gain, visual disturbances, dizziness, arthralgia, haematuria, impotence.
|Composit caution of TRIFORMIN :|
Elderly, malnourished, Impaired alertness. Avoid alcohol, Careful monitoring of blood-glucose concentration. Adrenocortical insufficiency, Changes in diet or prolonged exercise may also provoke hypoglycaemia, Avoid in severe hepatic impairment. Pregnancy, lactation.
Patients with pre-existing liver disease, kidney disease, heart trouble or if have any allergy, infections. Avoid excessive use of alcohol while taking this. It is not recommended for use during pregnancy and should be used only if clearly needed during lactation.
Increased risk of hypoglycaemia when used with insulin or oral hypoglycaemics. Oedema, congestive heart failure, hepatic dysfunction, jaundice, anaemia. May cause ovulation in premenopausal, anovulatory women. Monitor liver function before and during treatment. Monitor glycaemic control.